Piramal Pharma LimitedNSE: PPLPHARMA

Press Release Apr 28 2026

· Issued by Piramal Pharma Limited

Filed with NSE · · 39 pages · English

Summary by 6ix AI

The report highlights a transitional year impacted by external disruptions, but the company expects a return to growth in the upcoming fiscal year. Key developments include the completion of the Kenalog acquisition and a focus on cost optimization to mitigate revenue impacts. The company also reported no increase in net debt compared to the previous fiscal year, indicating stable financial management.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Piramal Pharma Limited on 6ix

In the deck

Earlier from Piramal Pharma

Later from Piramal Pharma

All Piramal Pharma news releases